X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (238) 238
oncology (226) 226
female (140) 140
male (137) 137
middle aged (128) 128
index medicus (122) 122
aged (119) 119
antineoplastic combined chemotherapy protocols - therapeutic use (104) 104
adult (93) 93
chemotherapy (90) 90
lung neoplasms - drug therapy (72) 72
treatment outcome (72) 72
carcinoma, non-small-cell lung - drug therapy (70) 70
colorectal neoplasms - drug therapy (51) 51
neoplasm staging (50) 50
cancer (49) 49
lung neoplasms - pathology (48) 48
disease-free survival (44) 44
carcinoma, non-small-cell lung - pathology (43) 43
colorectal neoplasms - pathology (43) 43
survival (43) 43
colorectal cancer (42) 42
survival analysis (42) 42
survival rate (40) 40
antineoplastic combined chemotherapy protocols - adverse effects (39) 39
fluorouracil (39) 39
animals (38) 38
fluorouracil - administration & dosage (35) 35
cisplatin - administration & dosage (34) 34
neoplasm metastasis (33) 33
prognosis (33) 33
therapy (33) 33
carcinoma (32) 32
leucovorin (32) 32
aged, 80 and over (31) 31
chemotherapy, adjuvant (31) 31
trial (30) 30
antineoplastic agents - therapeutic use (29) 29
lung neoplasms - mortality (29) 29
1st-line treatment (28) 28
carcinoma, non-small-cell lung - mortality (28) 28
leucovorin - administration & dosage (28) 28
hematology, oncology and palliative medicine (27) 27
oxaliplatin (26) 26
quality of life (26) 26
antibodies, monoclonal - therapeutic use (24) 24
combined modality therapy (24) 24
prospective studies (24) 24
surgery (24) 24
cisplatin (23) 23
immunotherapy (23) 23
mice (23) 23
randomized controlled trials as topic (23) 23
respiratory system (23) 23
care and treatment (22) 22
disease progression (21) 21
drug administration schedule (21) 21
vinblastine - analogs & derivatives (21) 21
deoxycytidine - analogs & derivatives (20) 20
randomized phase-iii (20) 20
time factors (20) 20
bevacizumab (19) 19
camptothecin - analogs & derivatives (19) 19
phase-iii trial (19) 19
5-fluorouracil (18) 18
cetuximab (18) 18
colonic neoplasms - immunology (18) 18
deoxycytidine - administration & dosage (18) 18
docetaxel (18) 18
phase-iii (18) 18
vinblastine - administration & dosage (18) 18
irinotecan (17) 17
kaplan-meier estimate (17) 17
metastasis (17) 17
open-label (17) 17
radiotherapy (17) 17
adenocarcinoma - drug therapy (16) 16
capecitabine (16) 16
clinical trials as topic (16) 16
combination (16) 16
fluorouracil - therapeutic use (16) 16
follow-up studies (16) 16
infusions, intravenous (16) 16
life sciences (16) 16
lung cancer (16) 16
non-small cell lung cancer (16) 16
tumors (16) 16
vinorelbine plus cisplatin (16) 16
analysis (15) 15
carcinoma, non-small-cell lung - therapy (15) 15
cell lung-cancer (15) 15
liver neoplasms - secondary (15) 15
lung neoplasms - therapy (15) 15
mutation (15) 15
organoplatinum compounds - administration & dosage (15) 15
panitumumab (15) 15
rats (15) 15
research (15) 15
adjuvant chemotherapy (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 11/2013, Volume 369, Issue 22, pp. 2159 - 2160
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 09/2014, Volume 9, Issue 9, pp. 1345 - 1353
Journal Article
Annals of oncology, ISSN 0923-7534, 2016, Volume 27, Issue 8, pp. 1386 - 1422
Journal Article
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25, Issue 7, pp. 1346 - 1355
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2013, Volume 369, Issue 11, pp. 1023 - 1034
Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,... 
SURVIVAL | 1ST-LINE TREATMENT | LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | RANDOMIZED PHASE-III | CETUXIMAB PLUS IRINOTECAN | BRAF | KRAS CODON 12 | FLUOROURACIL | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Membrane Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Fluorouracil - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Leucovorin - therapeutic use | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Organoplatinum Compounds - therapeutic use | Care and treatment | Dosage and administration | Research | Gene mutations | Panitumumab | Colorectal cancer | Hypothesis testing | Medical research | Statistical analysis | Epidermal growth factor receptors | Colorectal carcinoma | Metastasis | Cancer therapies | Survival | Patients | Metastases | Studies | Hypotheses | Chemotherapy | Epidermal growth factor | Oxaliplatin | Testing laboratories | Medical prognosis | Biomarkers | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 143 - 155
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2017, Volume 28, Issue 8, pp. 1862 - 1868
Background: Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on... 
First-line | RAS wild-type | Tumor sidedness | Panitumumab | Metastatic colorectal cancer | LOCATION | LEUCOVORIN | METAANALYSIS | MCRC | tumor sidedness | BEVACIZUMAB | PROXIMAL COLON | panitumumab | FLUOROURACIL | COLON-CANCER | CETUXIMAB | ONCOLOGY | FREE SURVIVAL PFS | first-line | metastatic colorectal cancer | Original
Journal Article